Wound, Ostomy and Continence Nurses Society (WOCN) Practice Exam

Oxygen toxicity during hyperbaric oxygen therapy (HBOT) can be a concern, especially with certain chemotherapeutic agents. The option indicating "all of the above" is correct because doxorubicin, Adriamycin (a brand name for doxorubicin), and sulfamylon (mafenide acetate) all can pose risks when used in conjunction with HBOT due to their potential to generate reactive oxygen species and enhance the effects of oxygen therapy.

When these medications are administered, they can create a scenario where the oxidative stress on the cells is amplified in a hyperbaric environment, leading to complications such as pulmonary toxicity or central nervous system effects. Understanding the interactions between these chemotherapeutics and HBOT is crucial for managing patient care safely. Therefore, it's important to be cautious and monitor patients who are undergoing treatment with these drugs while also receiving HBOT.